Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $218.00
Krystal Biotech (NASDAQ:KRYS – Free Report) had its price objective boosted by Chardan Capital from $212.00 to $218.00 in a research note released on Thursday,Benzinga reports. Chardan Capital currently has a buy rating on the stock. KRYS has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $221.00 […]
Krystal Biotech (NASDAQ:KRYS – Free Report) had its price objective boosted by Chardan Capital from $212.00 to $218.00 in a research note released on Thursday,Benzinga reports. Chardan Capital currently has a buy rating on the stock. KRYS has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $221.00 […]